Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study of SC-007 in Subjects With Advanced Cancer

Trial Profile

An Open Label Study of SC-007 in Subjects With Advanced Cancer

Phase of Trial: Phase I

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs SC-007 (Primary)
  • Indications Colorectal cancer; Gastric cancer
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 25 Apr 2018 Status changed from recruiting to discontinued due to benefit/risk imbalance
    • 27 Sep 2017 Planned End Date changed from 14 Jul 2021 to 28 Jul 2021.
    • 27 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top